Last updated: October 16, 2026
Kemstro was a branded orally disintegrating formulation of baclofen, an established generic muscle relaxant used to treat spasticity. Its commercial opportunity was limited by the age of the active ingredient, widespread availability of low-cost baclofen tablets, and the absence of a durable product-level market moat. Public filings do not disclose Kemstro-specific revenue. The product’s commercial trajectory is best characterized as a niche formulation launch followed by declining relevance as generic baclofen became the standard treatment.
What is Kemstro and what drug does it contain?
Kemstro contains baclofen, a gamma-aminobutyric acid-B receptor agonist used to reduce skeletal-muscle spasticity. The product was supplied as orally disintegrating tablets in 10-mg and 20-mg strengths.
| Attribute |
Kemstro |
| Active ingredient |
Baclofen |
| Dosage form |
Orally disintegrating tablet |
| Strengths |
10 mg and 20 mg |
| Therapeutic category |
Antispasticity agent |
| Primary use |
Spasticity associated with neurological disorders |
| U.S. sponsor |
Schwarz Pharma, later associated with UCB |
| FDA application |
NDA 21-673 |
| Reference drug class |
Baclofen tablets, including Lioresal |
| Current commercial position |
Legacy or discontinued branded product; generic baclofen dominates |
The formulation offered a potential adherence advantage for patients who had difficulty swallowing conventional tablets. That advantage did not materially change the underlying market structure because standard baclofen tablets were inexpensive, widely distributed, and clinically familiar.
The FDA labeling identifies baclofen as a treatment for spasticity and warns about central nervous system depression, weakness, dizziness, confusion, and withdrawal risks associated with abrupt discontinuation.[1]
When did Kemstro receive FDA approval and lose commercial exclusivity?
Kemstro entered a market in which baclofen had already been approved in the United States decades earlier. The active ingredient therefore did not receive new-chemical-entity exclusivity when Kemstro was introduced.
| Milestone |
Approximate timing |
Commercial effect |
| Original U.S. approval of baclofen |
1970s |
Established a mature active-ingredient market |
| Kemstro approval |
Early 2000s |
Introduced a branded orally disintegrating formulation |
| Generic baclofen tablets |
Long established before and during Kemstro commercialization |
Created immediate price pressure |
| UCB ownership of Schwarz Pharma |
2006 |
Shifted the product into UCB’s portfolio |
| Later market status |
Legacy/discontinued commercial product |
Generic baclofen remained the principal treatment option |
Kemstro did not have the exclusivity profile of a newly discovered medicine. Its commercial protection depended on formulation differentiation, trademarks, distribution, and any formulation-related patent rights rather than exclusivity for baclofen itself.
The FDA’s Orange Book does not provide Kemstro with the type of durable market protection associated with an active ingredient protected by a long-lived composition-of-matter patent. The key commercial barrier was therefore weak relative to products supported by new molecular entity patents.[2]
What patents protect Kemstro?
Kemstro’s potential intellectual-property protection centered on the orally disintegrating dosage form, not on baclofen as a molecule.
Publicly available regulatory records do not establish a currently active, commercially meaningful Kemstro patent estate capable of blocking standard baclofen tablets. Any formulation patent would have been vulnerable to design-around strategies involving tablet excipients, disintegration mechanisms, manufacturing processes, or alternative oral dosage forms.
Formulation patents
A formulation patent covering a baclofen orally disintegrating tablet could have protected:
- Rapid disintegration in the mouth
- Taste masking
- Excipient combinations
- Tablet compression parameters
- Moisture-control methods
- Manufacturing processes
- Dose uniformity and stability
Those claims would not necessarily prevent competitors from selling conventional baclofen tablets. They also would not block injectable or intrathecal baclofen products.
The commercial importance of such patents was limited because prescribers could substitute ordinary generic tablets for patients who did not require the ODT format.
Method-of-use patents
Kemstro was not associated with a high-value method-of-use patent strategy. Baclofen’s principal indication, treatment of spasticity, was already established. New indications or dosing methods could have supported additional intellectual property, but no major public commercial franchise developed around such claims.
Orange Book status
The Orange Book is the relevant source for listed patents and regulatory exclusivity for approved small-molecule drugs. Kemstro’s competitive position does not appear to depend on an active Orange Book patent blocking generic baclofen tablets. The principal approved competition is not a direct ODT substitute alone; it is the broader class of generic baclofen products that physicians and pharmacies can substitute based on patient needs.[2]
How many patents cover Kemstro?
The number of commercially relevant active patents is effectively zero based on the product’s mature regulatory status and lack of a visible current patent barrier in FDA listing data.
That conclusion should be separated from historical patent activity. A product may have had formulation or process patents at launch that later expired, lapsed, or ceased to have practical commercial value. Expiration of those rights would have removed a possible barrier to competing ODT formulations without changing the broader substitution threat from generic baclofen tablets.
What was Kemstro’s market position versus generic baclofen?
Kemstro competed in a highly price-sensitive market. Generic baclofen tablets were available in multiple strengths and became the default option for routine outpatient prescribing.
| Market factor |
Effect on Kemstro |
| Established generic active ingredient |
Reduced pricing power |
| Conventional tablets available at low cost |
Limited ODT premium |
| Familiarity with standard baclofen |
Favored generic substitution |
| ODT convenience |
Created a narrow adherence niche |
| No major new indication |
Limited market expansion |
| Retail pharmacy substitution |
Reduced branded retention |
| Low treatment cost |
Made premium positioning difficult |
Kemstro’s differentiation was functional rather than therapeutic. The ODT format could be useful for patients with dysphagia, difficulty handling tablets, or adherence problems. However, those segments were too narrow to support a large branded market without strong reimbursement or a substantial price advantage.
Payers generally had a reason to prefer generic baclofen tablets. A prescription for a branded ODT would need to justify incremental cost through adherence, swallowing limitations, or another patient-specific factor.
What is Kemstro’s financial trajectory?
No public filing identifies Kemstro revenue, gross margin, prescription volume, or operating profit as a separate line item. UCB and its predecessor Schwarz Pharma reported results at broader product or business-unit levels rather than providing a standalone Kemstro income statement.[3][4]
The likely financial trajectory was:
- Launch phase: Revenue generated from formulation differentiation and branded prescribing.
- Early erosion: Generic baclofen remained available, limiting market share and pricing.
- Portfolio-stage commercialization: Sales became dependent on a small group of patients for whom the ODT format offered practical value.
- Decline or discontinuation: Commercial returns likely failed to justify continued promotion, manufacturing complexity, or distribution costs.
Kemstro was not a major revenue driver for UCB. UCB’s strategic value was concentrated in larger neurological and immunology products, including medicines with stronger clinical differentiation and more substantial intellectual-property protection. Kemstro’s economics were more consistent with a low-revenue legacy product than with a growth asset.
Revenue exposure
The principal financial exposure associated with Kemstro was limited:
- Low probability of material revenue growth
- High exposure to generic price competition
- Little or no meaningful patent cliff because generic erosion was already embedded
- Limited risk from biosimilars
- Limited contribution to consolidated UCB revenue
- Possible manufacturing and supply-chain costs disproportionate to sales
The product’s financial decline would have been gradual rather than tied to one major patent expiration. Generic substitution and limited patient demand were more important than a single loss-of-exclusivity event.
Which companies challenged Kemstro and its market?
The main competitive pressure came from manufacturers of generic baclofen tablets rather than from a heavily litigated branded rival.
Generic baclofen suppliers have included multiple companies over time, with products distributed through retail pharmacies, wholesalers, hospitals, and mail-order channels. The competitive field has generally included manufacturers such as:
- Teva Pharmaceuticals
- Amneal Pharmaceuticals
- Rising Pharmaceuticals
- Major Pharmaceuticals
- ANI Pharmaceuticals
- Other FDA-approved generic suppliers depending on market period
The competitive threat was broad because any approved generic baclofen tablet could displace a branded prescription where the ODT feature was not medically necessary.
No major public Paragraph IV campaign is associated with Kemstro as a commercially significant litigation event. This reflects the product’s limited value as a target and the availability of straightforward non-ODT generic alternatives.
What is the FDA regulatory status of Kemstro?
Kemstro was approved through the FDA’s NDA pathway as a prescription baclofen product. It was not a biologic and therefore does not face biosimilar competition.
| Regulatory issue |
Assessment |
| FDA pathway |
New drug application |
| Product type |
Small-molecule prescription drug |
| Biosimilar exposure |
None |
| Generic exposure |
High |
| Active ingredient status |
Long-established |
| Regulatory differentiation |
Dosage-form convenience |
| Current commercial relevance |
Limited |
The key regulatory distinction is between the branded ODT product and ordinary baclofen tablets. FDA approval of generic baclofen tablets does not require the same ODT design, but those products still compete for the same underlying spasticity treatment market.
What generic launch risks exist for Kemstro?
Generic launch risk was structurally high from the beginning because baclofen was already a mature generic active ingredient. A company seeking to compete directly with an ODT product would face two separate paths:
- Develop a bioequivalent or therapeutically substitutable baclofen ODT.
- Sell conventional baclofen tablets at a lower price.
The second path is commercially stronger in most cases. It avoids the additional formulation-development requirements of an ODT while benefiting from pharmacy substitution and established prescribing habits.
Generic manufacturers also face limited incentives to pursue a branded-equivalent ODT if the total market is small. This can reduce the number of direct ODT competitors while leaving the broader tablet market highly competitive.
What manufacturing and intellectual-property barriers affected Kemstro?
Kemstro’s ODT formulation required more specialized manufacturing than standard compressed tablets. Relevant technical requirements could include:
- Controlled tablet friability
- Rapid oral disintegration
- Taste masking
- Moisture protection
- Packaging that limits tablet breakage
- Consistent dose delivery
- Stability through distribution
These requirements could create manufacturing friction, but they were not equivalent to a durable patent barrier. Once formulation know-how became available or patents expired, the remaining barriers were mainly operational and economic.
The product also faced a scale problem. A low-volume ODT may carry higher per-unit production and packaging costs, while standard baclofen tablets benefit from large-scale generic manufacturing.
How does Kemstro compare with other baclofen products?
| Product or category |
Differentiation |
Patent strength |
Generic pressure |
Commercial outlook |
| Kemstro |
Oral disintegrating tablet |
Low to limited |
High |
Legacy niche |
| Generic baclofen tablets |
Low-cost standard oral dosage form |
Minimal |
Internal generic competition |
Dominant outpatient option |
| Lioresal tablets |
Original branded baclofen |
Historical brand recognition |
High |
Limited relative to generics |
| Intrathecal baclofen |
Specialized delivery system |
Higher clinical and device complexity |
Lower than oral tablets |
Specialty-market product |
| Gablofen |
Intrathecal baclofen injection |
Product and delivery differentiation |
Moderate |
Hospital and specialty use |
Intrathecal baclofen should not be treated as a direct substitute in every patient. It is used in more severe cases and requires specialist administration, pump management, and monitoring. Its economics and regulatory profile are materially different from Kemstro’s oral outpatient market.
What litigation and settlement agreements affected Kemstro?
No major, publicly material Kemstro patent litigation or settlement agreement is associated with the product’s commercial history. The absence of prominent litigation is consistent with:
- An old active ingredient
- Limited product revenue
- No major composition-of-matter patent
- A weak incentive to litigate against standard baclofen tablets
- The availability of non-infringing generic dosage forms
The principal commercial event was market substitution, not a litigated patent cliff.
What is the competitive outlook for Kemstro?
Kemstro has little remaining growth potential as a branded product. Any residual demand would be concentrated among patients who benefit from orally disintegrating administration and cannot obtain equivalent value from conventional tablets.
The most probable market outcomes are:
| Scenario |
Probability assessment |
Financial effect |
| Continued broad branded growth |
Low |
Unlikely to produce material revenue |
| Small residual niche |
Moderate |
Limited, patient-specific sales |
| Full commercial withdrawal |
Plausible |
Removes low-value legacy revenue and costs |
| Direct generic ODT competition |
Possible |
Further reduces pricing power |
| Generic standard-tablet substitution |
Persistent |
Primary long-term pressure |
Key Takeaways
- Kemstro is a baclofen orally disintegrating tablet, not a new molecular entity.
- Its commercial differentiation was convenience, not superior efficacy.
- Generic baclofen tablets created substantial substitution pressure from launch.
- No durable, high-value patent estate appears to support the product today.
- Public filings do not disclose Kemstro-specific revenue or profitability.
- The product was unlikely to represent material exposure for UCB.
- No significant Paragraph IV litigation or settlement history is publicly associated with Kemstro.
- Biosimilar risk is irrelevant because baclofen is a small molecule.
- The product’s likely financial trajectory was niche launch, generic erosion, and eventual commercial decline.
- Standard generic baclofen tablets remain the principal competitive benchmark.
FAQs About Kemstro Market Dynamics
Is Kemstro still available in the United States?
Kemstro has a legacy or discontinued commercial profile, while generic baclofen tablets remain broadly available. FDA application and product records should be distinguished from actual commercial distribution status.[2]
Is Kemstro the same as Lioresal?
Both contain baclofen, but Kemstro was an orally disintegrating formulation. Lioresal historically referred to branded baclofen products, including oral and intrathecal formulations.
Does Kemstro have biosimilar competition?
No. Biosimilars apply to biologic products. Kemstro contains the small-molecule drug baclofen and faces generic-drug competition instead.
Why did generic baclofen threaten Kemstro even without an identical ODT?
Generic tablets treat the same underlying condition and are substantially less expensive. Physicians and payers can use them when a patient does not specifically require orally disintegrating administration.
Was Kemstro an important UCB revenue product?
There is no public evidence that Kemstro was a material contributor to UCB’s consolidated revenue. UCB’s financial reporting did not separately identify Kemstro sales, and the product operated in a low-price generic market.
References
-
U.S. Food and Drug Administration. (n.d.). Kemstro (baclofen) orally disintegrating tablets prescribing information. Drugs@FDA.
-
U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations. Orange Book.
-
UCB. (2006). Annual report 2006. UCB S.A.
-
UCB. (2023). Annual report 2023. UCB S.A.
